Clinical trial
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head…
NCT00244439 · Sun Pharmaceutical Industries, Inc., Industry · Completed
Key facts
| NCT number | NCT00244439 |
|---|---|
| Title | Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice |
| Official title | A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05%Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis |
| Lead sponsor | Sun Pharmaceutical Industries, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lice Infestations |
| Intervention type | Drug |
| Interventions | MALG, Ovide (malathion) lotion 0.05%, Permethrin 1% |
| Enrollment | 360 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Oct 26, 2005 |
| Last update posted | Dec 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: